| [1] |
Tamirou F, Arnaud L, Talarico R, et al. Systemic lupus erythematosus: state of the art on clinical practice guidelines [J]. RMD Open, 2018, 4(2): e000793.
|
| [2] |
Musa R, Brent L, Qurie A. Lupus nephritis [M]. Treasure Island (FL): StatPearls Publishing, 2020.
|
| [3] |
Imran TF, Yick F, Verma S, et al. Lupus nephritis: an update [J]. Clin Exp Nephrol, 2016, 20(1): 1-13.
|
| [4] |
Hanaoka H, Kiyokawa T, Iida H, et al. Comparison of renal response to four different induction therapies in Japanese patients with lupus nephritis class Ⅲ or Ⅳ：a single-centre retrospective study [J]. PLoS One, 2017, 12(4): e0175152.
|
| [5] |
Tsokos GC, Lo MS, Costa Reis P, et al. New insights into the immunopathogenesis of systemic lupus erythematosus [J]. Nat Rev Rheumatol, 2016, 12(12): 716-730.
|
| [6] |
Lamagna C, Hu Y, DeFranco AL, et al. B cell-specific loss of Lyn kinase leads to autoimmunity [J]. J Immunol, 2014, 192(3): 919-928.
|
| [7] |
Espeli M, Bökers S, Giannico G, et al. Local renal autoantibody production in lupus nephritis [J]. J Am Soc Nephrol, 2011, 22(2): 296-305.
|
| [8] |
Goenka R, Matthews A, Zhang B, et al. Local BlyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation [J]. J Exp Med, 2014, 211(1): 45-56.
|
| [9] |
Samy E, Wax S, Huard B, et al. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases [J]. Int Rev Immunol, 2017, 36(1): 3-19.
|
| [10] |
MacKay F, Schneider P. Cracking the BAFF code [J]. Nat Rev Immunol, 2009, 9(7): 491-502.
|
| [11] |
Zhang Y, Li J, Zhang YM, et al. Effect of TACI signaling on humoral immunity and autoimmune diseases [J]. J Immunol Res, 2015, 2015: 247426.
|
| [12] |
Figgett WA, Deliyanti D, Fairfax KA, et al. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers [J]. J Autoimmun, 2015, 61: 9-16.
|
| [13] |
Jiang C, Loo WM, Greenley EJ, et al. B cell maturation antigen deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus [J]. J Immunol, 2011, 186(11): 6136-6147.
|
| [14] |
Melchers F. Actions of BAFF in B cell maturation and its effects on the development of autoimmune disease [J]. Ann Rheum Dis, 2003, 62(Suppl 2): ii25-ii27.
|
| [15] |
Smulski CR, Eibel H. BAFF and BAFF-receptor in B cell selection and survival [J]. Front Immunol, 2018, 9: 2285.
|
| [16] |
Jacob CO, Yu N, Guo S, et al. Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor [J]. Arthritis Rheum, 2013, 65(4): 1043-1054.
|
| [17] |
Fassbinder T, Saunders U, Mickholz E, et al. Dierential efects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus [J]. Arthritis Res Ther, 2015, 17(1): 92.
|
| [18] |
Yap DY, Tang C, Ma MK, et al. Longterm data on disease flares in patients with proliferative lupus nephritis in recent years [J]. J Rheumatol, 2017, 44(9): 1375-1383.
|
| [19] |
Deng J, Xie H, Zhu L, et al. Maintenance therapy for lupus nephritis with mycophenolate mofetil or azathioprine. A meta-analysis [J]. Clin Nephrol, 2019, 91(3): 172-179.
|
| [20] |
Wallin EF, Hill DL, Linterman MA, et al. The calcineurin inhibitor tacrolimus specifically suppresses human T follicular helper cells [J]. Front Immunol, 2018, 9: 1184.
|
| [21] |
Traitanon O, Mathew JM, La Monica G, et al. Dierential effects of tacrolimus versus sirolimus on the proliferation, activation and dierentiation of human B cells [J]. PLoS One, 2015, 10(6): e0129658.
|
| [22] |
Zhang H, Liu Z, Huang L, et al. The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis [J]. Lupus, 2017, 26(9): 952-958.
|
| [23] |
温晓莹，肖慧捷，王芳，等. 利妥昔单抗治疗儿童系统性红斑狼疮合并狼疮性肾炎5例临床观察 [J]. 广东医学，2020, 41(8): 831-834.
|
| [24] |
Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with Rituximab study [J]. Arthritis Rheum, 2012, 64(4): 1215-1226.
|
| [25] |
Merrill JT, June J, Koumpouras F, et al. 98 results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb5871, in systemic lupus erythematosus [J]. Lupus Sci Med, 2019, 6(Suppl 1): A73-A74.
|
| [26] |
Clowse ME, Wallace DJ, Furie RA, et al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials [J]. Arthritis Rheumatol, 2017, 69(2): 362-375.
|
| [27] |
Kansal R, Richardson N, Neeli I, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus [J]. Sci Transl Med, 2019, 11(482): eaav1648.
|
| [28] |
Ramskold D, Parodis I, Lakshmikanth T, et al. B cell alterations during BAFF inhibition with belimumab in SLE [J]. EBioMedicine, 2019, 40: 517-527.
|
| [29] |
Merrill JT, Shanahan WR, Scheinberg M, et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial [J]. Ann Rheum Dis, 2018, 77(6): 883-889.
|
| [30] |
Lorenzetti R, Janowska I, Smulski CR, et al. Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells [J]. J Autoimmun, 2019, 101: 145-152.
|
| [31] |
Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study [J]. Arthritis Rheumatol, 2014, 66(2): 379-389.
|
| [32] |
Almaani S, Rovin BH. B-cell therapy in lupus nephritis: an overview [J]. Nephrol Dial Transplant, 2019, 34(1): 22-29.
|
| [33] |
Xiang L, Liu A, Xu G. Expression of XBP1s in B lymphocytes is critical for pristane-induced lupus nephritis in mice [J]. Am J Physiol Renal Physiol, 2020, 318(5): F1258-F1270.
|